Document Classification

Section Type: METHODS

Text: In this double-blind, phase 2 trial undertaken in 196 sites in 36 countries, 3241 patients with non-ST-elevation acute coronary syndromes were randomly assigned via a central, telephone-based interactive voice response system to one of five doses of otamixaban (0. 08 mg/kg bolus followed by infusions of 0. 035 [n = 125], 0. 070 [676], 0. 105 [662], 0. 140 [658], or 0. 175 [671] mg/kg/h) or to a control of unfractionated heparin (60 IU/kg intravenous bolus followed by an infusion of 12 IU/kg/h) plus eptifibatide (180 microg/kg intravenous bolus followed by an infusion of 1. 0-2. 0 microg/kg/min [n = 449]).